Figure 7.
Figure 7. Cotreatment with LBH589 and AMN107 depletes the levels of Bcr-Abl, p-CrkL, and p-STAT5 in IM-resistant primary CML-BC cells. Two purified samples of IM-resistant CML-BC cells, sample 5 without a known mutation in Bcr-Abl (A) and sample 9 with expression Bcr-AblT315I (B), were exposed to LBH589 and/or AMN107 for 24 hours. Following this, the cell lysates were harvested and immunoblotted with the anti–Bcr-Abl, p-CrkL, or p-anti–p-STAT5 antibody. The levels of β-actin served as the loading control.

Cotreatment with LBH589 and AMN107 depletes the levels of Bcr-Abl, p-CrkL, and p-STAT5 in IM-resistant primary CML-BC cells. Two purified samples of IM-resistant CML-BC cells, sample 5 without a known mutation in Bcr-Abl (A) and sample 9 with expression Bcr-AblT315I (B), were exposed to LBH589 and/or AMN107 for 24 hours. Following this, the cell lysates were harvested and immunoblotted with the anti–Bcr-Abl, p-CrkL, or p-anti–p-STAT5 antibody. The levels of β-actin served as the loading control.

Close Modal

or Create an Account

Close Modal
Close Modal